Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

NCT02470871 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Coagulation Factor VII Deficiency

Interventions

BIOLOGICAL: Eptacog alfa (activated) or pdFVII
BIOLOGICAL: CSL689

Sponsor

CSL Behring